ILC/EASL Updates for HB surgeons

ILC/EASL 2019 Excited to see major interest in our work @ILC2019, EASL in Vienna. Thank you @Medizin Medien Austria for featuring our results and surgical highlights of the congress with an interview – great pleasure. https://medonline.at/innere-medizin/onkologie/krebshilfe/easl-ilc/2019/10028197/easl-ilc-2019-leber-aus-dem-labor-und-weitere-highlights-fuer-chirurgen/

ASO -Author Reflection

Ever found it puzzling that a patient with more than 12 months of neoadjuvant chemotherapy flies trough postoperative recovery after major liver resection without any signs of chemotherapy associated steatohepatitis (CASH) on histology, while some patients after only 2 months of systemic therapy struggle significantly due to chemotherapy associated liver Read more…

Micro RNAs in HB surgery

Remember your last patient developing liver failure after liver resection? Proofs of our recent work on miRNAs in liver surgery are out now demonstrating that miRNAs are sensitive markers for preoperative liver function and predict postoperative outcomes – freely available on: https://lnkd.in/dUq25YG A major step towards personalized medicine in HB Read more…

Non-invasive CASH assessment

Ever found it puzzling that a patient with more than 12 months of neoadjuvant chemotherapy flies trough postoperative recovery after major liver resection without any signs of chemotherapy associated steatohepatitis (CASH) on histology, while some patients after only 2 months of systemic therapy struggle significantly due to chemotherapy associated liver Read more…